BiotechTV - News
BiotechTV
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Episodes
Mentioned books
Aug 5, 2025 • 6min
From Indianapolis: Adipo Therapeutics is approaching the obesity space by trying to turn energy storing 'white' fat into energy burning 'brown' fat
CEO Karen Wurster describes the science behind the company, which recently presented proof-of-concept data from human cells at the ADA meeting. Plus, what it is like working from the IBRI in Indianapolis and being an Indiana biotech company.
Aug 5, 2025 • 9min
The Indiana Biosciences Research Institute is a central hub for the biotech scene in Indiana - its CEO describes what it is all about, and the status of biotech here today
IBRI CEO Alan Palkowitz descrbies the work that takes place at the IBRI, which includes both the institute's own research and how it acts as an incubator to biotech companies. Plus, the state of biotech in Indiana and what its strengths are here.
Aug 4, 2025 • 11min
BiotechTV visits Indiana University School of Medicine's Stark Neurosciences Research Institute and discusses the latest in Alzheimer's research with its executive director, Bruce Lamb
Dr. Lamb, a noted expert in neuroscience and Alzheimer's research, introduces us to Stark and describes the investment in people and equipment that has been made here. The institute has two key focuses of 1) modeling Alzheimer's disease and 2) how to expedite research understandings to treat it. Plus, he discusses a company he has co-founded, called Monument Biosciences, that is focusing on the neuroinflamatory side of the disease.
Jul 30, 2025 • 26min
Former NIH Director and Co-Founder of ModeX Therapeutics Elias Zerhouni shares his take on possible NIH cuts and the state of science in the United States, and working on multispecifics at his company
He highlights his new memoir, Disease Knows No Politics, and gives his opinion on what is at stake in preserving NIH and other scientific funding. Plus, how ModeX is working on multispecifics for cancer and autoimmune conditions, and multivalent vaccines.
Jul 25, 2025 • 10min
AI x Bio Summit: Proscia CEO David West describes how AI in pathology is not just helping pathologists find disease, but can also help get the right drug to the right patient
He describes how computing power in pathology is augmenting the work that pathologists traditionally do, but also is becoming an increasing important tool in precision medicine.
Jul 24, 2025 • 19min
Monte Rosa Therapeutics' CEO Markus Warmuth updates us on the company's progress in developing molecular glue degraders
The company, which recently had a paper earn a spot on the cover of Science, is progressing ahead with both I&I and oncology indications. Dr. Warmuth walks us through the pipeline progress and overall strategy of finding and pursuing targets.
Jul 24, 2025 • 27min
Abivax CEO Marc de Garidel discusses Obefazimod's phase 3 trial result in ulcerative colitis, and what is next for the company
He covers the mechanism of action, this week's efficacy and safety data, what it might mean for the maintenance trial that will read out in 2Q26, additional indications, IP, business development, and more.
Jul 24, 2025 • 15min
AI x Bio Summit: Recursion's Chief R&D Officer & CCO Najat Khan describes how the company leverages AI - including in both the dry lab and the wet lab, and all through clinical trials
She describes Recursion's work, and what the acquisition of Exscientia has brought to the company. Plus, how AI can not only help with drug design, but also safety and patient recruitment.
Jul 23, 2025 • 20min
After receiving a CRL for its RP1 oncolytic immunotherapy yesterday, the CEO of Replimune walks us through the program's timeline and history, and what this might mean for its future
CEO Sushil Patel walks us through the decisions behind the design of the IGNYTE phase 1/2 study and the ongoing IGNYTE-3 study, he gives Replimune's impression of how the review went since the BLA was filed last November, and he discusses what the CRL could mean for the future.
Jul 23, 2025 • 11min
AI x Bio Summit: The CEO of Alto Neuroscience, which is working on precision medicine for neuroscience, talks about how the company is using AI and machine learning in its development programs
Amit Etkin says Alto Neuro is trying to use machine learning to understand signals from the complexity of the brain, and the company is also embedding AI in its clinical trials in order to collect as much information from the field as possible. He also walks us through the company's program.
